Westpac Banking Corp trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 30.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 7,081 shares of the medical research company’s stock after selling 3,133 shares during the period. Westpac Banking Corp’s holdings in Natera were worth $2,927,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in NTRA. Trust Co. of Vermont bought a new position in shares of Natera during the second quarter valued at $26,000. Elevation Wealth Partners LLC bought a new position in Natera in the 2nd quarter worth about $30,000. Continuum Advisory LLC bought a new position in Natera in the 2nd quarter worth about $33,000. Rakuten Securities Inc. purchased a new stake in Natera during the 2nd quarter valued at about $35,000. Finally, Transamerica Financial Advisors LLC purchased a new stake in Natera during the 2nd quarter valued at about $39,000. 99.90% of the stock is owned by institutional investors.
Insider Activity at Natera
In other news, insider Solomon Moshkevich sold 3,419 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $409.77, for a total value of $1,401,003.63. Following the completion of the sale, the insider owned 101,323 shares in the company, valued at approximately $41,519,125.71. This trade represents a 3.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 470 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $391.49, for a total value of $184,000.30. Following the completion of the transaction, the chief financial officer directly owned 45,779 shares in the company, valued at $17,922,020.71. This trade represents a 1.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 47,056 shares of company stock worth $17,760,989 in the last quarter. 5.05% of the stock is owned by company insiders.
Analysts Set New Price Targets
Several brokerages have recently issued reports on NTRA. BTIG Research upped their target price on shares of Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a research note on Tuesday, October 27th. Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Thursday, October 15th. Stephens upped their price objective on Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, Canaccord Genuity Group increased their target price on Natera from $375.00 to $500.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $394.31.
View Our Latest Report on Natera
Natera Trading Up 0.1%
Shares of NTRA stock opened at $289.92 on Friday. Natera, Inc. has a 12-month low of $181.00 and a 12-month high of $437.41. The stock has a market capitalization of $42.04 billion, a P/E ratio of -254.32 and a beta of 1.55. The firm’s 50 day moving average is $376.63 and its 200 day moving average is $272.74.
Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14). The firm had revenue of $793.98 million for the quarter, compared to the consensus estimate of $707.54 million. Natera had a negative net margin of 5.66% and a negative return on equity of 8.61%. Natera’s quarterly revenue was up 34.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.64) earnings per share. As a group, equities analysts predict that Natera, Inc. will post -1.25 earnings per share for the current year.
Natera Profile
Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.
Featured Stories
- Five stocks we like better than Natera
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
